174 related articles for article (PubMed ID: 17145891)
1. Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide.
Yanagisawa K; Exley MA; Jiang X; Ohkochi N; Taniguchi M; Seino K
Cancer Res; 2006 Dec; 66(23):11441-6. PubMed ID: 17145891
[TBL] [Abstract][Full Text] [Related]
2. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide.
Hayakawa Y; Takeda K; Yagita H; Kakuta S; Iwakura Y; Van Kaer L; Saiki I; Okumura K
Eur J Immunol; 2001 Jun; 31(6):1720-7. PubMed ID: 11385616
[TBL] [Abstract][Full Text] [Related]
3. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.
Sharif S; Arreaza GA; Zucker P; Mi QS; Sondhi J; Naidenko OV; Kronenberg M; Koezuka Y; Delovitch TL; Gombert JM; Leite-De-Moraes M; Gouarin C; Zhu R; Hameg A; Nakayama T; Taniguchi M; Lepault F; Lehuen A; Bach JF; Herbelin A
Nat Med; 2001 Sep; 7(9):1057-62. PubMed ID: 11533711
[TBL] [Abstract][Full Text] [Related]
4. NKT cells act as regulatory cells rather than killer cells during activation of NK cell-mediated cytotoxicity by alpha-galactosylceramide in vivo.
Chamoto K; Takeshima T; Kosaka A; Tsuji T; Matsuzaki J; Togashi Y; Ikeda H; Nishimura T
Immunol Lett; 2004 Aug; 95(1):5-11. PubMed ID: 15325792
[TBL] [Abstract][Full Text] [Related]
5. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice.
Hong S; Wilson MT; Serizawa I; Wu L; Singh N; Naidenko OV; Miura T; Haba T; Scherer DC; Wei J; Kronenberg M; Koezuka Y; Van Kaer L
Nat Med; 2001 Sep; 7(9):1052-6. PubMed ID: 11533710
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of the synthetic ligand-mediated function of liver NK1.1Ag+ T cells in mice by interleukin-12 pretreatment.
Habu Y; Uchida T; Inui T; Nakashima H; Fukasawa M; Seki S
Immunology; 2004 Sep; 113(1):35-43. PubMed ID: 15312134
[TBL] [Abstract][Full Text] [Related]
7. Enhanced gamma interferon production through activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide in interleukin-18-deficient mice with systemic cryptococcosis.
Kawakami K; Kinjo Y; Yara S; Uezu K; Koguchi Y; Tohyama M; Azuma M; Takeda K; Akira S; Saito A
Infect Immun; 2001 Nov; 69(11):6643-50. PubMed ID: 11598033
[TBL] [Abstract][Full Text] [Related]
8. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.
Fujii S; Shimizu K; Kronenberg M; Steinman RM
Nat Immunol; 2002 Sep; 3(9):867-74. PubMed ID: 12154358
[TBL] [Abstract][Full Text] [Related]
9. alpha-galactosylceramide induces early B-cell activation through IL-4 production by NKT cells.
Kitamura H; Ohta A; Sekimoto M; Sato M; Iwakabe K; Nakui M; Yahata T; Meng H; Koda T; Nishimura S; Kawano T; Taniguchi M; Nishimura T
Cell Immunol; 2000 Jan; 199(1):37-42. PubMed ID: 10675273
[TBL] [Abstract][Full Text] [Related]
10. Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes.
Burdin N; Brossay L; Koezuka Y; Smiley ST; Grusby MJ; Gui M; Taniguchi M; Hayakawa K; Kronenberg M
J Immunol; 1998 Oct; 161(7):3271-81. PubMed ID: 9759842
[TBL] [Abstract][Full Text] [Related]
11. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide.
Toura I; Kawano T; Akutsu Y; Nakayama T; Ochiai T; Taniguchi M
J Immunol; 1999 Sep; 163(5):2387-91. PubMed ID: 10452972
[TBL] [Abstract][Full Text] [Related]
12. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma.
Kikuchi A; Nieda M; Schmidt C; Koezuka Y; Ishihara S; Ishikawa Y; Tadokoro K; Durrant S; Boyd A; Juji T; Nicol A
Br J Cancer; 2001 Sep; 85(5):741-6. PubMed ID: 11531261
[TBL] [Abstract][Full Text] [Related]
13. Ligand-activated natural killer T lymphocytes promptly produce IL-3 and GM-CSF in vivo: relevance to peripheral myeloid recruitment.
Leite-de-Moraes MC; Lisbonne M; Arnould A; Machavoine F; Herbelin A; Dy M; Schneider E
Eur J Immunol; 2002 Jul; 32(7):1897-904. PubMed ID: 12115609
[TBL] [Abstract][Full Text] [Related]
14. In vivo activation of invariant V alpha 14 natural killer T cells by alpha-galactosylceramide sequentially induces Fas-dependent and -independent cytotoxicity.
Lisbonne M; Hachem P; Tonanny MB; Fourneau JM; Sidobre S; Kronenberg M; Van Endert P; Dy M; Schneider E; Leite-de-Moraes MC
Eur J Immunol; 2004 May; 34(5):1381-8. PubMed ID: 15114671
[TBL] [Abstract][Full Text] [Related]
15. Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alpha-galactosylceramide.
Chiba A; Oki S; Miyamoto K; Hashimoto H; Yamamura T; Miyake S
Arthritis Rheum; 2004 Jan; 50(1):305-13. PubMed ID: 14730629
[TBL] [Abstract][Full Text] [Related]
16. Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases.
Kojo S; Adachi Y; Keino H; Taniguchi M; Sumida T
Arthritis Rheum; 2001 May; 44(5):1127-38. PubMed ID: 11352245
[TBL] [Abstract][Full Text] [Related]
17. Role of Valpha 14 NKT cells in the development of impaired liver regeneration in vivo.
Ito H; Ando K; Nakayama T; Taniguchi M; Ezaki T; Saito K; Takemura M; Sekikawa K; Imawari M; Seishima M; Moriwaki H
Hepatology; 2003 Nov; 38(5):1116-24. PubMed ID: 14578850
[TBL] [Abstract][Full Text] [Related]
18. Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis.
Hayakawa Y; Rovero S; Forni G; Smyth MJ
Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9464-9. PubMed ID: 12867593
[TBL] [Abstract][Full Text] [Related]
19. CD1d-restricted NKT regulatory cells: functional genomic analyses provide new insights into the mechanisms of protection against Type 1 diabetes.
Mi QS; Meagher C; Delovitch TL
Novartis Found Symp; 2003; 252():146-60; discussion 160-4, 203-10. PubMed ID: 14609217
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
Giaccone G; Punt CJ; Ando Y; Ruijter R; Nishi N; Peters M; von Blomberg BM; Scheper RJ; van der Vliet HJ; van den Eertwegh AJ; Roelvink M; Beijnen J; Zwierzina H; Pinedo HM
Clin Cancer Res; 2002 Dec; 8(12):3702-9. PubMed ID: 12473579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
